ACER: AI 评分 38/100 — AI 分析 (4月 2026)

Acer Therapeutics Inc. is a pharmaceutical company focused on acquiring, developing, and commercializing therapies for serious rare and life-threatening diseases. Their pipeline includes clinical-stage candidates targeting vascular Ehlers-Danlos Syndrome, urea cycle disorders, and infectious diseases.

Key Facts: AI Score: 38/100 Sector: Healthcare

公司概况

概要：

Acer Therapeutics Inc. is a biopharmaceutical company specializing in the development of treatments for rare and life-threatening diseases, focusing on clinical-stage assets like EDSIVO and ACER-001. With a lean structure and strategic collaborations, Acer aims to address unmet medical needs in niche therapeutic areas within the biotechnology sector.

ACER是做什么的？

Acer Therapeutics Inc., founded in 1991 and headquartered in Newton, Massachusetts, is a pharmaceutical company dedicated to the acquisition, development, and commercialization of therapies for serious rare and life-threatening diseases, also known as orphan diseases. The company's strategy involves identifying and acquiring promising clinical-stage assets that have the potential to address significant unmet medical needs. Acer's pipeline currently features four clinical-stage product candidates: EDSIVO (celiprolol) for the treatment of vascular Ehlers-Danlos Syndrome (vEDS) in patients with a confirmed type III collagen mutation; ACER-001, a formulation of sodium phenylbutyrate, for the treatment of urea cycle disorders (UCDs) and Maple Syrup Urine Disease (MSUD); ACER-801 (osanetant) for induced Vasomotor Symptoms (iVMS); and ACER-2820 (emetine), a host-directed therapy against a variety of infectious diseases, including COVID-19. Acer collaborates with organizations like the National Center for Advancing Translational Sciences (NCATS) to advance its research and development efforts. The company also has a license agreement with Sanofi for worldwide rights to osanetant. Acer operates with a relatively small team of 30 employees, reflecting its focus on efficient development and strategic partnerships.

ACER的投资论点是什么？

Acer Therapeutics presents a focused investment opportunity within the rare disease space. The company's value drivers include the potential approval and commercialization of EDSIVO for vEDS, a disease with limited treatment options. Positive clinical trial outcomes and regulatory approvals for ACER-001 in UCDs and MSUD could also significantly enhance shareholder value. The development of ACER-2820 as a host-directed therapy for infectious diseases provides further upside potential. However, the company faces risks related to clinical trial outcomes, regulatory hurdles, and the ability to secure funding for ongoing development programs. With a P/E ratio of -0.40 and a beta of 0.44, Acer demonstrates high risk and volatility. Successful execution of its clinical programs and strategic partnerships are critical for realizing its potential.

ACER在哪个行业运营？

Acer Therapeutics operates within the biotechnology industry, which is characterized by high research and development costs, lengthy regulatory approval processes, and significant market potential for successful products. The rare disease market is a growing segment within the biotechnology industry, driven by increasing awareness, regulatory incentives, and the potential for high drug prices. Competition comes from both large pharmaceutical companies and smaller biotech firms focused on developing therapies for specific rare diseases. Acer's success depends on its ability to navigate the complex regulatory landscape, secure funding for its clinical programs, and effectively commercialize its products.

Biotechnology

Healthcare

ACER有哪些增长机遇？

EDSIVO for vascular Ehlers-Danlos Syndrome (vEDS): The market for vEDS treatments is largely untapped, with limited existing therapies. Successful clinical trials and regulatory approval for EDSIVO could establish Acer as a leader in this space. The potential market size is estimated to be significant, given the lack of effective treatments and the severity of the disease. Timeline for potential approval and commercialization is dependent on clinical trial outcomes and regulatory review, with potential launch within the next 2-3 years.
ACER-001 for Urea Cycle Disorders (UCDs) and Maple Syrup Urine Disease (MSUD): ACER-001 offers a potentially improved formulation of sodium phenylbutyrate, addressing a known need in the treatment of UCDs and MSUD. The market for these metabolic disorders is established, with existing therapies providing a benchmark for pricing and market penetration. Positive clinical data and regulatory approval could allow ACER-001 to capture a significant share of this market. Timeline for potential approval and commercialization is dependent on clinical trial outcomes and regulatory review, with potential launch within the next 2-3 years.
ACER-801 (osanetant) for induced Vasomotor Symptoms (iVMS): Acer acquired worldwide rights to osanetant from Sanofi, a clinical-stage asset targeting iVMS. This presents an opportunity to address a significant unmet need in women's health. The market for iVMS treatments is substantial, driven by the prevalence of menopause and the associated symptoms. Successful development and commercialization of osanetant could generate significant revenue for Acer. Timeline for potential approval and commercialization is dependent on clinical trial outcomes and regulatory review, with potential launch within the next 3-5 years.
ACER-2820 (emetine) as a host-directed therapy for infectious diseases, including COVID-19: The collaboration with NCATS to develop emetine hydrochloride as a potential treatment for COVID-19 represents a significant growth opportunity. Host-directed therapies offer a novel approach to treating infectious diseases by targeting host cell mechanisms rather than the pathogen itself. The market for COVID-19 treatments remains substantial, and successful development of ACER-2820 could provide a valuable therapeutic option. Timeline for potential approval and commercialization is dependent on clinical trial outcomes and regulatory review, with potential launch within the next 2-4 years.
Strategic Partnerships and Acquisitions: Acer's business model focuses on acquiring and developing promising clinical-stage assets. Continued success in identifying and securing strategic partnerships and acquisitions will be crucial for expanding its pipeline and driving long-term growth. The company's expertise in rare diseases and its lean operational structure position it well to capitalize on opportunities in the biotechnology sector. Timeline for potential partnerships and acquisitions is ongoing, with the company actively seeking new opportunities to expand its portfolio.

Acer Therapeutics focuses on therapies for rare and life-threatening diseases, a market with high unmet needs and potential for premium pricing.
The company's pipeline includes four clinical-stage candidates, diversifying its risk and potential revenue streams.
Acer has a research collaboration agreement with NCATS to develop emetine hydrochloride as a potential treatment for patients with COVID-19, showcasing innovation in infectious disease.
A license agreement with Sanofi grants Acer worldwide rights to osanetant, expanding its portfolio with a clinical-stage asset.
With 30 employees, Acer operates with a lean structure, potentially reducing operational costs.

ACER提供哪些产品和服务？

Acquire therapies for rare and life-threatening diseases.
Develop clinical-stage drug candidates.
Focus on unmet medical needs in niche therapeutic areas.
Seek regulatory approvals for their drug candidates.
Commercialize approved therapies.
Collaborate with research institutions and pharmaceutical companies.

ACER如何赚钱？

Acquire rights to promising drug candidates.
Develop and conduct clinical trials to demonstrate efficacy and safety.
Obtain regulatory approvals from agencies like the FDA.
Commercialize approved drugs through partnerships or internal sales teams.

Patients with rare and life-threatening diseases.
Healthcare providers who treat these patients.
Hospitals and clinics that administer the therapies.
Payers, including insurance companies and government healthcare programs.

Focus on rare diseases provides market exclusivity and pricing power.
Intellectual property protection through patents and regulatory exclusivity.
Strategic partnerships with research institutions and pharmaceutical companies.
Specialized expertise in developing therapies for rare diseases.

什么因素可能推动ACER股价上涨？

Upcoming: Potential regulatory approval and commercial launch of EDSIVO for vascular Ehlers-Danlos Syndrome (vEDS).
Upcoming: Clinical trial results for ACER-001 in Urea Cycle Disorders (UCDs) and Maple Syrup Urine Disease (MSUD).
Upcoming: Progress in the development of ACER-2820 as a host-directed therapy for infectious diseases.
Ongoing: Strategic partnerships and acquisitions to expand the company's pipeline.
Ongoing: Advancements in drug development technologies to improve the efficiency and effectiveness of clinical trials.

ACER的主要风险是什么？

Potential: Clinical trial failures for key drug candidates.
Potential: Regulatory setbacks and delays in obtaining approvals.
Potential: Competition from larger pharmaceutical companies with greater resources.
Ongoing: Dependence on securing funding to support clinical development programs.
Ongoing: Patent expirations and loss of market exclusivity.

ACER的核心优势是什么？

Focus on rare diseases with high unmet needs.
Pipeline of clinical-stage drug candidates.
Strategic collaborations with research institutions and pharmaceutical companies.
Lean operational structure.

ACER的劣势是什么？

Reliance on successful clinical trial outcomes.
Dependence on regulatory approvals.
Limited financial resources.
Small team size.

ACER有哪些机遇？

Expansion of pipeline through acquisitions and partnerships.
Potential for orphan drug designation and market exclusivity.
Growing awareness and demand for rare disease therapies.
Advancements in drug development technologies.

ACER面临哪些威胁？

Clinical trial failures.
Regulatory setbacks.
Competition from larger pharmaceutical companies.
Patent expirations.

ACER的竞争对手是谁？

American Healthcare Holdings, Inc. — Focuses on healthcare services rather than drug development. — (AMHV)
Axelar Acquisition Corp. — A special purpose acquisition company (SPAC), not a direct competitor in drug development. — (AXLA)
Elevance Health Inc. — A health insurance company, not a direct competitor in drug development. — (ELEV)
Imunon, Inc. — Focuses on immunotherapy for cancer, different therapeutic area. — (IMNN)
Kineta, Inc. — Focuses on developing immunotherapies, different therapeutic area. — (KA)

Key Metrics

MoonshotScore: 38/100

Company Profile

CEO: Christopher Schelling
Headquarters: Newton, US
Employees: 30
Founded: 2004

AI Insight

AI analysis pending for ACER

常见问题

What does Acer Therapeutics Inc. do?

Acer Therapeutics Inc. is a biopharmaceutical company focused on the acquisition, development, and commercialization of therapies for serious rare and life-threatening diseases. The company's pipeline includes clinical-stage candidates targeting vascular Ehlers-Danlos Syndrome (vEDS), urea cycle disorders (UCDs), Maple Syrup Urine Disease (MSUD), induced Vasomotor Symptoms (iVMS), and infectious diseases like COVID-19. Acer's strategy involves identifying and acquiring promising assets, conducting clinical trials, and seeking regulatory approvals to bring these therapies to market, addressing unmet medical needs in niche therapeutic areas.

What do analysts say about ACER stock?

AI analysis is pending for ACER. Generally, analyst opinions on biotechnology companies like Acer are heavily influenced by clinical trial results, regulatory milestones, and market potential of their drug candidates. Key valuation metrics include the potential peak sales of their products, the probability of regulatory approval, and the company's cash runway. Investors should monitor analyst ratings and price targets, but also conduct their own due diligence to assess the risks and opportunities associated with ACER.

What are the main risks for ACER?

Acer Therapeutics faces several key risks inherent to the biotechnology industry. Clinical trial failures represent a significant risk, as negative results can halt the development of a drug candidate and significantly impact the company's valuation. Regulatory setbacks, such as delays in obtaining approvals or rejection of applications, can also negatively affect Acer's prospects. Competition from larger pharmaceutical companies with greater resources and established market presence poses a threat. Additionally, Acer is dependent on securing funding to support its clinical development programs, and any difficulty in raising capital could hinder its progress.